Warnings and Precautions

QT/QTc Interval Prolongation: Androgen deprivation therapy, such as ORGOVYX may prolong the QT/QTc interval. Providers should consider whether the benefits of androgen deprivation therapy outweigh the potential risks in patients with congenital long QT syndrome, congestive heart failure, or frequent electrolyte abnormalities and in patients taking drugs known to prolong the QT interval. Electrolyte abnormalities should be corrected. Consider periodic monitoring of electrocardiograms and electrolytes.

ORGOVYX™ and its associated logo are trademarks of Myovant Sciences, Inc.
©2021 Myovant Sciences GmbH and Pfizer Inc. All rights reserved. PP-US-REL-2100119 04/21